Compare Fastly Inc (FSLY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fastly Inc trades at $24.34 (market cap $3.98B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Fastly Inc is far larger — about 4.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Fastly Inc is more actively traded (6,072,668 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FSLY | MRVI | |
|---|---|---|
Market Cap | $3.98B | $977.37M |
Volume | 6,072,668 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $33.50 | $9.00 |
52-Week Low | $7.86 | $2.83 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $4.04B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $27.09, up 2.5% with bullish technical signals and strong earnings beats. The stock shows improving fundamentals with revenue growth from $544M to $624M (2024-2025) and narrowing losses. Recent investor day highlighted AI-driven growth targets of $1.1-1.3B revenue by 2029. Technical indicators show bullish moving averages with support at $25 and resistance at $28.
Outlook remains positive with analyst consensus at $28.33 target, though risks include persistent net losses and insider selling. The company's edge cloud platform benefits from AI traffic growth, but profitability challenges and competitive pressures require monitoring. Institutional sentiment is mixed with 33% buy ratings amid ongoing transformation.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
